About the Company
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development. In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis. In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc. In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease. On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. As part of the deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three more RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ARWR News
Arrowhead Pharmaceuticals Inc (ARWR) Surge: Is It Sustainable?
Arrowhead Pharmaceuticals Inc (ARWR) stock saw a modest uptick, ending the day at $20.78 which represents a slight increase of $0.77 or 3.85% from the prior close of $20.01. The stock opened at $20 ...
Arrowhead Pharmaceuticals Inc (ARWR) Stock Rated Neutral by Goldman
Arrowhead Pharmaceuticals Inc (ARWR) stock saw a modest uptick, ending the day at $21.49 which represents a slight increase of $1.25 or 6.18% from the prior close of $20.24. The stock opened at $20.39 ...
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from TD Cowen
TD Cowen analyst Brendan Smith maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today. The company’s ...
Strong Buy Rating for Arrowhead Pharmaceuticals’ Plozasiran Based on Positive Clinical Trial Outcomes and Market Potential
Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), retaining the ...
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as ...
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present new Phase 3 clinical data from the PALISADE study of plozasiran (ARO-APOC3) at the European Society of ...
Arrowhead Pharmaceuticals Inc ARWR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran ...
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 3 PALISADE study of investigational ...
ARWR Arrowhead Pharmaceuticals, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
September 10, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy ...
Arrowhead Pharmaceuticals, Inc. (ARWR)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...